Transition Therapeutics (Transition Therapeutics) Net Cash per Share : $0.36 (As of Mar. 2016)

Transition Therapeutics Net Cash per Share Chart

Transition Therapeutics Annual Data
	Trend	Jun06	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15
Net Cash per Share		Get a 7-Day Free Trial					0.78	0.51	0.85	1.32	0.57

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Net Cash per Share	Get a 7-Day Free Trial															0.82	0.57	0.45	0.41	0.36

Competitive Comparison of Transition Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Transition Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transition Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transition Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Transition Therapeutics's Price-to-Net-Cash falls into.

Transition Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Transition Therapeutics's Net Cash per Share for the fiscal year that ended in Jun. 2015 is calculated as

Transition Therapeutics's Net Cash per Share for the quarter that ended in Mar. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transition Therapeutics  (NAS:TTHI) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Transition Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description